PEGS-The Chain Episode 40



Dr. Nimish Gera, Head of Biologics at Mythic Therapeutics, sits down with Christina Lingham, Executive Director of Conferences and Fellow at Cambridge Healthtech Institute, in this Episode of the Chain to talk about how the developability of bispecific antibodies topic came about, how the field is changing, new bispecific molecules coming through the pipeline, and his expectations for the future.

BIOs

Nimish Gera, PhDNimish Gera, PhD, Head, Biologics, Mythic Therapeutics
Nimish Gera is the Head of Biologics at Mythic Therapeutics leading multiple projects to engineer and develop novel antibody and antibody-based drugs in oncology and immuno-oncology. Prior to Mythic, Nimish has over ten years of experience in antibody and protein engineering with five years leading bispecific antibody programs in several disease areas such as rare diseases, oncology and immunology at Alexion Pharmaceuticals and Oncobiologics. Nimish received his PhD degree in Chemical and Biomolecular Engineering from North Carolina State University and a B.Tech degree in Chemical Engineering from Indian Institute of Technology, Guwahati.

PEGS Summer Europe

Peptalk